% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • sbum55 sbum55 Nov 12, 2012 11:37 PM Flag

    Already... Next generation ADC's

    Very interesting to see the PBDs advancing. Was this derived from a deal with Spirogen? Can't see to find anything specific on that. Genentech has a deal from Spirogen (2011 press release) for evaluation of the PBDs. Looks like Spirogen has evaluation deals with other biotech/pharma too but specifics don't seem to be disclosed. Can't seem to dig up anything specific on Spirogen/SGEN either, but the SGN-33 ASH abstract is linked under news on Spirogen's website...

    Hopefully we'll get some clarity on ownership of the technology, terms of the deal (if any), # of targets SGEN has rights to, etc, post ASH? Unclear whether this actually opens up door to whole new round of collaboration deals for Seagen or perhaps future competition? Good to see them pursuing all options for advancing the best internal product candidates either way though!

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just to clarify, from SGEN 4/3/12 press release: "Under an agreement with Spirogen, Seattle Genetics has developed a single PBD molecule that is being evaluated for future clinical-candidate ADCs."

      haven't been able to find more specifics about the deal and what rights SGEN has to this specific PBD molecule.

      Sentiment: Buy

45.30+1.32(+3.00%)Aug 26 4:00 PMEDT